BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8347733)

  • 1. Comparison of 5 vs 10 micrograms/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancer.
    Bokemeyer C; Schmoll HJ; Metzner B; Beyer J; Illiger HJ; Kneba M; Ostermann H; Kynast B; Räth U; Poliwoda H
    Ann Hematol; 1993 Aug; 67(2):75-9. PubMed ID: 8347733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin/etoposide/ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with far-advanced testicular carcinoma.
    Harstrick A; Schmoll HJ; Bokemeyer C; Metzner B; Illiger HJ; Berdel W; Ostermann H; Manegold C; Räth U; Siegert W
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S198-202. PubMed ID: 1665492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours.
    Bokemeyer C; Schmoll HJ; Harstrick A; Illiger HJ; Metzner B; Räth U; Hohnloser J; Clemm C; Berdel W; Siegert W
    Eur J Cancer; 1993; 29A(16):2225-31. PubMed ID: 8110490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Colony stimulating factors in polychemotherapy of testicular tumors. A comparison between G-CSF and GM-CSF].
    Will R; Hofmockel G; Langer W; Frohmüller H
    Urologe A; 1999 May; 38(3):258-63. PubMed ID: 10407985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer.
    Fanning J; Hilgers RD
    Gynecol Oncol; 1996 Dec; 63(3):323-7. PubMed ID: 8946866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin.
    Brugger W; Frisch J; Schulz G; Pressler K; Mertelsmann R; Kanz L
    J Clin Oncol; 1992 Sep; 10(9):1452-9. PubMed ID: 1517788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemotherapy.
    Bokemeyer C; Kuczyk MA; Köhne H; Einsele H; Kynast B; Schmoll HJ
    Ann Hematol; 1996 Jan; 72(1):1-9. PubMed ID: 8605273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF.
    Ford PA; Arbuck SG; Minniti C; Miller LL; DeMaria D; O'Dwyer PJ
    Eur J Cancer; 1996 Apr; 32A(4):631-5. PubMed ID: 8695266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer.
    Thongprasert S
    J Med Assoc Thai; 2000 May; 83(5):549-53. PubMed ID: 10863902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of granulocyte-macrophage colony-stimulating factor in the treatment of germ cell tumors. German Testicular Cancer Study Group.
    Bokemeyer C; Harstrick A; Rüther U; Metzner B; Illiger HJ; Clemm C; Siegert W; Link H; Ostermann H; Schmoll HJ
    Semin Oncol; 1994 Dec; 21(6 Suppl 16):57-63. PubMed ID: 7801148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
    Steward WP; von Pawel J; Gatzemeier U; Woll P; Thatcher N; Koschel G; Clancy L; Verweij J; de Wit R; Pfeifer W; Fennelly J; von Eiff M; Frisch J
    J Clin Oncol; 1998 Feb; 16(2):642-50. PubMed ID: 9469353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of rhGM-CSF on haematopoietic reconstitution after chemotherapy in small-cell lung cancer.
    Havemann K; Klausmann M; Wolf M; Fischer JR; Drings P; Oster W
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S203-7. PubMed ID: 1665493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
    Graziano SL; Valone FH; Herndon JE; Crawford J; Richards F; Rege VB; Clamon G; Green MR
    Lung Cancer; 1996 Jun; 14(2-3):315-29. PubMed ID: 8794413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability and efficacy of GM-CSF [Leucomax] in patients with small cell lung cancer treated with intensive chemotherapy.
    Walewski J; Romejko-Jarosińska J; Zwoliński J; Falkowski S; Siedlecki P
    Med Oncol; 1996 Dec; 13(4):199-205. PubMed ID: 9152970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte-macrophage colony-stimulating factor given before dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP).
    Holdsworth MT; Roon R; Ferguson J; Martinez L; Stidley CA; Neidhart JA
    Biotechnol Ther; 1993; 4(3-4):183-95. PubMed ID: 8292969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy.
    Marina NM; Shema SJ; Bowman LC; Rodman J; Douglass EC; Furman WL; Pappo A; Santana VM; Hudson M; Meyer WH
    Med Pediatr Oncol; 1994; 23(4):328-34. PubMed ID: 8058003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
    Brugger W; Birken R; Bertz H; Hecht T; Pressler K; Frisch J; Schulz G; Mertelsmann R; Kanz L
    Br J Haematol; 1993 Jul; 84(3):402-7. PubMed ID: 7692928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies.
    Shaffer DW; Smith LS; Burris HA; Clark GM; Eckardt JR; Fields SM; Weiss GR; Rinaldi DA; Bowen KJ; Kuhn JG
    Cancer Res; 1993 Dec; 53(24):5929-33. PubMed ID: 8261405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced germ cell tumours by dose intensified chemotherapy with haematopoietic growth factors or peripheral blood stem cells (PBSC).
    Bokemeyer C; Schmoll HJ
    Eur Urol; 1993; 23(1):223-9; discussion 230. PubMed ID: 8097467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.